Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis.
Bert AvauHans Van RemoortelJorien LaermansGeertruida BekkeringDean FergussonJørgen GeorgsenPaola Maria ManziniYves OzierEmmy De BuckVeerle CompernollePhilippe VandekerckhovePublished in: PharmacoEconomics (2021)
Cost effectiveness of preoperative iron is unproven, whereas routine preoperative ESA therapy cannot be considered cost effective in elective surgery, based on the limited available data. Future guidelines should reflect these findings.
Keyphrases
- patients undergoing
- minimally invasive
- end stage renal disease
- coronary artery bypass
- clinical practice
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- surgical site infection
- prognostic factors
- electronic health record
- big data
- stem cells
- current status
- acute coronary syndrome
- mesenchymal stem cells
- percutaneous coronary intervention
- data analysis